Plaintiff

Eli Lilly and Company

8 cases as plaintiff.

Cases
8
Active
0
8 closed
Filed
2008
Top venue
S.D. Indiana
7 cases

Company profile

Eli Lilly and Company ("Lilly") — Lilly Corporate Center, Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly; incorporated in Indiana in 1901. Publicly traded on the NYSE under ticker LLY. It is one of the largest research-based pharmaceutical companies, reporting 2024 revenue of approximately $45.0 billion and roughly 47,000–50,000 employees worldwide (Lilly 10-K / lilly.com). No parent company; it is the ultimate parent.

Operations. Lilly discovers, develops, manufactures, and markets human pharmaceutical products as a single business segment, selling in approximately 95 countries with manufacturing in the U.S. (including Puerto Rico), Europe, and Asia. Major therapy areas include diabetes (insulins such as Humalog and Humulin; Jardiance and related products through a global agreement with Boehringer Ingelheim), obesity and metabolic disease (tirzepatide brands Mounjaro and Zepbound), oncology, immunology (e.g., Taltz), and neuroscience (e.g., Cymbalta/duloxetine, Zyprexa/olanzapine). It also operates LillyDirect, a U.S. direct-to-consumer digital health platform. This is an operating company, not an NPE or licensing shell.

Litigation posture. Lilly is an operating company and a one-way patent plaintiff in this dataset: 8 tracked cases as plaintiff, 0 as defendant. All are Hatch-Waxman (ANDA) infringement suits against generic manufacturers, filed in Lilly's home venue, the U.S. District Court for the Southern District of Indiana (Indianapolis Division) — not a plaintiff-friendly NPE venue such as the Eastern District of Texas.

Notable cases. The tracked 2008 filings — against Sun Pharmaceutical, Lupin, Aurobindo, Wockhardt, Actavis Elizabeth, Impax, Sandoz, and Cobalt Laboratories — followed ANDA filings seeking approval of generic duloxetine hydrochloride (Cymbalta) capsules, then Lilly's second-best-selling drug, ahead of patent expiry in 2013. This framework also reflects Lilly's broader branded-drug defense program of that era, including olanzapine (Zyprexa) and duloxetine patent challenges in the U.S. and abroad.

Keep this research.

Save to your free workspace, then choose whether to receive updates.

Eli Lilly and Company v. Lupin Limited et al.

dismissed
Docket:
1:08-cv-01596
Filed:
2008-11-24
Terminated:
2011-04-27
Patents:5023269

Lilly sued Lupin for infringement of US 5,023,269 in the Cymbalta/duloxetine HCl ANDA litigation. The case was dismissed by stipulation/consent order on April 27, 2011, converting Paragraph IV certifications to Paragraph III, with no appeal.

Eli Lilly and Company v. Wockhardt Limited et al.

judgment
Docket:
1:08-cv-01547
Terminated:
2011-03-21
Patents:5023269

Lilly sued Wockhardt and related entities for infringement of claims 10 and 11 of US 5,023,269. The court entered final judgment for Lilly on March 21, 2011, finding infringement and upholding validity and enforceability. The lead case number was 1:08-cv-1547-TWP-TAB.